Clinical Observation Of Deanxit In The Treatment Of Refractory Functional Bowel Disease Accompanied By Anxiety And Depression

Objective: With the increasing of economic and social pressure,the prevalence of refractory functional bowel disease(FBDs)with anxiety and depression increases year by year.At present,the etiology and pathogenesis of the disease are not clear,and the diagnosis mainly depends on clinical symptoms.However,there is no effective clinical basis for multi-factor diagnosis,and the treatment effect is not ideal and the quality of life is poor.This study,on the one hand,provides a basis for multi-factor diagnosis of diseases,and helps doctors to improve the ability of disease recognition.On the other hand,it provides clinical thinking and reference for optimizing the diagnosis and treatment strategy of diseases.Methods:(1)Selection on June 6,2018-December 2019 in Jilin Provincial People’s Hospital digestive clinic because of abdominal pain,abdominal distention,diarrhea,constipation symptoms related to accord with standard of Roman Ⅳ FBDs patients with refractory FBDs for recurrent symptoms,Seventy-two patients with refractory FBDs were selected as the FBDs group.Refractory FBDs refers to FBDs patients who have no organic lesions confirmed by gastroenteroscopy,color doppler ultrasound and other relevant examinations and who have taken various conventional gastrointestinal drugs for more than3 months but have poor results.Seventy-two patients with refractory FBDs were selected as FBDs group.A total of 72 patients were selected as the control group(age and sex characteristics matched)in 1:1 ratio.Participants were asked to fill in the anxiety and depression self-rating scale(SAS,SDS),somatic symptom self-rating scale(SSS),gastrointestinal symptom assessment form(GSRS)(not filled in by the control group),and general information questionnaire.(2)Fifty-six refractory FBDs patients with anxiety and/or depression in the first part of the study were selected and combined with Deanxit on the basis of conventional drugs in physiological links of digestive tract for 8 weeks.The changes of abdominal pain,abdominal distention,constipation,diarrhea symptom severity,somatization disorder,anxiety,and depression were compared before and after treatment.The reduction rate of each score was compared to analyze the clinical efficacy,and the adverse drug reactions were observed.Results:(1)The prevalence rate of women in FBDs group was higher than that of men.The less educated you are,the more likely you are to have FBDs.There were significant differences in daily activity,family income,sleep quality,negative sexual events and psychological state scores between FBDs group and control group,which were statistically significant.The patients in FBDs group were characterized by anxiety and depression,severe somatization disorder,severe sleep disorder,high negative event positive rate,low family economic income and little daily activity.SAS and SDS scores with parenteral somatization disorder were significantly higher than those without somatization disorder(P<0.05),showing statistically significant differences.Patients with somatization disorder in FBDs group(66.67%)were significantly higher than those in the control group(30.56%),P<0.05,indicating a statistically significant difference.There were56 cases of upper gastrointestinal symptoms in FBDs group,accounting for 77.78%.(2)56 patients with anxiety and depression were treated with FBDs combined with Deanxit for 8 weeks,with a total effective rate of 91.07%.The total score of gastrointestinal symptoms after treatment was significantly lower than that before treatment(5.57±1.86 VS1.66±0.97,P=0.000),and the difference was statistically significant.GSRS score of all symptoms(abdominal pain,abdominal distension,diarrhea,constipation)decreased significantly(P < 0.05),the difference was statistically significant.The severity of anxiety and depression in the enrolled patients decreased significantly,and the number of people with anxiety and depression decreased significantly.In terms of efficacy,the mild and moderate effects were significant.SAS scores and SDS scores of FBDs patients with anxiety and depression were significantly lower than those before treatment(P < 0.05).SSS score significantly decreased before and after treatment,and somatization symptoms significantly improved(43.33±9.22 VS 34.75±8.12,P < 0.05),and the difference was statistically significant.Conclusion: 1、Anxiety,depression and somatization disorders are common in FBDs patients.Factors such as reduced activity,low family income,more negative sexual events,sleep disorders,and less daily activity affect the occurrence and progression of FBDs.2 、 Deanxit is effective in the treatment of gastrointestinal symptoms,anxiety and depression,and somatization disorders of FBDs.It can quickly and effectively relieve symptoms without obvious adverse reactions,and increase patients’ compliance and treatment confidence.Therefore,this drug is worth popularizing.